Sporozoite asparagine-rich protein 1 (SAP1) (SAP1)

Sporozoite asparagine-rich protein 1 (SAP1), also known as SLARP, is a critical protein in the life cycle of the malaria parasite Plasmodium falciparum (Aly et al., 2008, Mol Microbiol). It is primarily expressed in the sporozoite stage and is essential for the transition from the mosquito vector to the mammalian host's liver (Aly et al., 2011, Mol Microbiol). SAP1 functions as a post-transcriptional regulator by binding to and stabilizing specific mRNA transcripts, particularly those of the 'upregulated in infectious sporozoites' (UIS) gene family, such as UIS3 and UIS4 (UniProt Q8IHP9). These transcripts encode proteins that are vital for the formation of the parasitophorous vacuole and the subsequent development of the parasite within hepatocytes (Aly et al., 2008, Mol Microbiol). In the absence of SAP1, these essential transcripts are rapidly degraded, leading to a complete developmental arrest of the parasite at the early liver stage (Aly et al., 2011, Mol Microbiol). This characteristic makes SAP1 a primary target for the development of whole-organism malaria vaccines, specifically genetically attenuated parasites (GAPs) (van Schaijk et al., 2014, eLife). The PfGAP3KO vaccine, which incorporates a SAP1 deletion alongside P52 and P36, has demonstrated safety and immunogenicity in human clinical trials (Kublin et al., 2017, Sci Transl Med). While no small-molecule inhibitors of SAP1 are currently in clinical use, its indispensable role in parasite infectivity and liver-stage maturation makes it a significant focus for both vaccine research and potential future therapeutic interventions.

Other names

SLARPSporozoite and liver stage asparagine-rich proteinS22Sporozoite-specific gene 22

Targeted genetic deletion of SAP1 leads to the degradation of essential transcripts (UIS genes), causing developmental arrest in the liver stage and enabling the creation of live-attenuated vaccines.